### SBF-CM Folder Details

Folder ID: 120220

Reg No:

(b)(7)(E)

**Author**: (b)(6);(b)(7)(C)

ODEQ

Addressed To:

Location:

ODEQ

Due:

03/22/2012

Received:

3/12/2012

Date Sent:

3/22/2012

Security:

A-AES

Response:

(b)(4) 2012 procurement quota Increase for hydocodone

Abstract: Signature:

B. Boockholdt

Doc Categories:

Doc Types:

(b)(6);(b)(7)(C)

ODG

03/19/2012 3/19/2012

Action:

Recommendation and Comments



Subject Date

(b)(4);(b)(7)(E)

2012 Procurement Quota Increase Request

Hydrocodone (DFN: 630-08.2) MAR 1 2 2012

To

Barbara Boockholdt

Chief

Regulatory Section

Office of Diversion Control

Christine A.

Chief

UN Reporting and Quota Section

Office of Diversion Control

#### Background:

As a result of the recent increase in the diversion and abuse of hydrocodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains sales (broken out by customer) for 2011 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for hydrocodone.



Subject	Date
(b)(4);(b)(7)(E)  2012 Procurement Quota Increase Request	
Hydrocodone	MAR 1 6 2012
(DFN: 630-08.2)	
To From	achan Boockholdt
Christine A. Sannerud, Ph.D., Chief	rbara J. Boockholdt, Chief gulatory Section (ODG)
<b>21.09 00 01.1</b>	fice of Diversion Control
On March 12, 2012, this section received your memorandum	requesting a review of a quota increase
submitted by $(b)(4)$ ODQ is requesting a review of $(b)(4)$ curwhether the applicant's customers are currently under investig	stomer list, specifically, information on gation or are subject of an order to show
cause or immediate suspension order.	
ODGR conducted NADDIS and CSA reviews of approximate	ely ninety-two (92) of (b)(4) customers as
well as an in-depth investigation of (b)(4)	
The below listed information was found on (b)(4) customers	:
Cur	rently Under Review/Investigation
(b)(4);(b)(7)(E)	
Cui	rently Under Review/Investigation
(b)(4);(b)(7)(E)	
	rently Under Review/Investigation
(b)(4);(b)(7)(E)	
	rrently Under Review/Investigation
Cu	rently Onder Review/Investigation
	(b)(4);(b)( 7)(E)

	Currently Under Review/Investigation
	(b)(4);(b)(7)(E)
(b)(4);(b)(7)(E)	Retired
company. $(b)(4)$ has five (5) customers that ar	OG recommends that ODQ limit the quota granted to this re Under Review/Investigation and one (1) that is retired.
We are available to discuss quantitative levels to this information, please feel free to contact	s at your convenience. If you have any questions pertaining $\operatorname{me}_{\mathbb{C}}^{(b)(6);(b)(7)()}$ or $\operatorname{SC}^{(b)(6);(b)(7)(\mathbb{C})}$

SBF-CM Folder Details

Folder ID: 120391

Reg No:

(b)(7)(E)

Author: (b)(6);(b)(7)(C)

Addressed To:

Location:

ODEQ

Due:

03/30/2012

Received:

3/20/2012

Date Sent:

3/22/2012

Security:

A-AES

Response:

Abstract:

Unit Dose 2012 procurement quota increase for oxycodone memo

Signature:

B. Boockholdt

Doc Categories:

Doc Types:

(b)(6);(b)(7)(C)

ODG

03/29/2012 3/21/2012

Action:

Recommendation and Comments



Subject

Unit Dose (b)(4);(b)(7)(E)

2012 Procurement Quota Increase Request

Oxycodone

(DFN: 630-08.2)

Date

MAR 2 0 2012

Τo

Barbara Boockholdt

Chief

Regulatory Section

Office of Diversion Control

From

Christine A. Sanzerud, Ph.D.

Chief

UN Reporting & Quota Section Office of Diversion Control

#### Background:

As a result of the recent increase in the diversion and abuse of oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for hydrocodone.



Subject	Date
Unit Dose (b)(4);(b)(7)(E)  2012 Procurement Quota Increase Request Oxycodone (DFN:630-08.2)	MAR 2 1 2012

To

Christine A. Sannerud, Ph.D, Chief UN Reporting and Quota Section Office of Diversion Control Barbara J. Boockholdt, Chief Regulatory Section Office of Diversion Control

On March 20, 2012, this section received your memorandum requesting a review of Unit Dose's customers list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

Unit Dose provided a list of (b)(4) customers. The names of the customers were run through NADDIS to determine if there were any open field investigations. The DEA registration numbers were also run through RICS to determine if the registrations were current. These checks yielded the following results:

#### No derogatory information was found

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by Unit Dose for the quota increase.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7) or SC (b)(6);(b)(7)(C)

#### SBF-CM Folder Details

Folder ID: 120920

Reg No:

(b)(7)(E)

Author: (b)(6);(b)(7)(C)

ODEQ

Addressed To:

Location:

ODEQ

Due:

04/27/2012

Received:

4/17/2012

Date Sent:

4/23/2012

Security:

A-AES

Response:

Abstract:

(b)(4)

2012 procurement quota increase request for oxycodone

Signature: Doc Categories:

C. Sannerud

Doc Types:

(b)(6);(b)(7)(C)

ODG

04/24/2012 4/23/2012

Action:

Recommendation and Comments



Subject Date
(b)(4)

2012 Procurement Quota Increase Request

Oxycodone (DFN: 630-08.2)

APR 1 7 2012

To

Barbara Boockholdt

Chief

Regulatory Section

Office of Diversion Control

From

Christine A. Sannerud, Ph.D.

Chief

Drug & Chemical Evaluation Section

Office of Diversion Control


Background:

As a result of the recent increase in the diversion and abuse oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2011 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for oxycodone.



Subject (b)(4);(b)(7)(E)  2012 Procurement Quota Increase Request Oxycodone (DFN: 630-08.2)	APR 2 0 2012
To Christine A. Sannerud, Ph.D., Chief Drug & Chemical Evalutaion Section (ODQ) Office of Diversion Control	From  Barbara J. Boockholdt, Chief  Regulatory Section (ODG)  Office of Diversion Control
order to show cause or immediate suspension orde	iew of (b)(4)   customer list, specifically, are currently under investigation or are subject of an er.
The below listed information was found on (b)(4)	customers:  Currently Under Review/Investigation
(b)(4)	Currently Under Review/Investigation
(b)(4)	Currently Under Review/Investigation
(b)(4);(b	Currently Under Review/Investigation
	Currently Under Suspension



Based upon a review of (b)(4)	customers, ODG recommends that ODQ adjust the quota granted to
this company. One of (b)(4)	customer is currently under (b)(4);(b)(7)(E)
fourteen (14) customers are	under Review/Investigation; and three (3) are retired.
(1.)(4)	ed by at least the total kilogram amounts sold by the company to the
If you have any questions pertaining (b)(6);(b)(7)(C)	to this information, please feel free to contact me (b)(6);(b)(7)( or SC

SBF-CM
Folder Details

Folder ID: 120811

Reg No:

(b)(7)(E)

Author: (b)(6);(b)(7)(C)

Addressed To: Barbara Boockholdt

DEQ

ODEQ

Due:

04/22/2012

Received:

4/12/2012

Date Sent:

Location:

4/25/2012

Security:

A-AES

Response:

Abstract:

b)(4) 2012 procurement quota increase request for hydrocodone

Christine Sannerud

Signature: Doc Categories:

Doc Types:

(b)(6);(b)(7)(C)

ODG

04/19/2012 4/24/2012

Action:

Recommendation and Comments



Subject

(b)(4);(b)(7)(E)

2012 Procurement Quota Increase Request

Hydrocodone (DFN: 630-08.2)

APR 1 2 2012

Τo

Barbara Boockholdt

Chief

Regulatory Section

Office of Diversion Control

From

Christine A. Sannerud, P.

Date

Chief

UN Reporting and Quota Section

Office of Diversion Control

Background:

As a result of the recent increase in the diversion and abuse of hydrocodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for hydrocodone.



0.11	
Subject (b)(4);(b)(7)(E)	Date
2012 Procurement Quota Increase Request Hydrocodone (DFN: 630-08.2)	APR 2 3 2012
То	
UN Reporting and Quota Section (ODQ)  Regular	a J. Boockholdt, Chief tory Section (ODG) of Diversion Control
On April 12, 2012, this section received your memorandum requessibilities by $(b)(4)$ ODQ is requesting a review of $(b)(4)$ whether the applicant's customers are currently under investigation cause or immediate suspension order.	stomer list specifically information
ODGR conducted NADDIS and CSA reviews of approximately ni as well as on (b)(4)	nety-nine (99) of (b)(4) customers
The following information was found on $(b)(4)$ and the below list	eted customers:
Order to	Show Cause Requested
(b)(4);(b)(6);(b)(7)(C);(b)(7)(E)	
(b)(4);(b)(7)(E)	Under Review/Investigation
Currently	Under Review/Investigation
	(b)(4);(b)( 7)(E)

SBF-CM Folder Details

Folder ID: 120810

Reg No:

(b)(7)(E)

Author: (b)(6);(b)(7)(C)

Addressed To:,

ODEQ

Location:

ODEQ

Due:

04/22/2012

Received:

4/12/2012

Date Sent:

4/19/2012

Security:

A-AES

Response:

Abstract:

(b)(4) 2012 procurement quota inrease reuquest for oxycodone

Signature:

Barbara Boockholdt

Doc Categories:

Doc Types:

(b)(6);(b)(7)(C)

ODG

04/19/2012 4/18/2012

Action:

Recommendation and Comments



Subject (b)(4);(b)(7)(E)

2012 Procurement Quota Increase Request

Oxycodone

(DFN: 630-08.2)

Date

APR 1 2 2012

To

Barbara Boockholdt

Chief

Regulatory Section

Office of Diversion Control

From

Christine A. Sannerud, Ph

Chief

UN Reporting and Quota Section Office of Diversion Control

Background:

As a result of the recent increase in the diversion and abuse of oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for hydrocodone.



Subject (b)(4);(b)(7)(E)  2012 Procurement Quota Increase Request Oxycodone (DFN: 630-08.2)	Date APR 1 8 2012
Christine A. Sannerud, Ph.D., Chief UN Reporting and Quota Section (ODQ) Office of Diversion Control  From Barbara J. Boockholdt, Chief Regulatory Section (ODG) Office of Diversion Control	
On April 12, 2012, this section received your memorandum requesting a review of a quota increase submitted by (b)(4) ODQ is requesting a review of (b)(4) customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.  ODGR conducted NADDIS and CSA reviews of approximately forty-five (45) of (b)(4) customers as	
The following information was found on (b)(4) and the below listed customers:  Currently Under Review/Investigation (b)(4);(b)(7)(E)	
Currently Under Review/Investigation (b)(4);(b)(7)(E)	
Because two of $(b)(4)$ customers are currently under rev ODQ adjust the quota allotted to $(b)(4)$ accordingly.  If you have any questions pertaining to this information, ple $(b)(6)(b)(7)(C)$	iew/investigation, ODG recommends that ase feel free to contact $me_{C)}^{(b)(6);(b)(7)()}$ or SC

# SBF-CM Folder Details

Politic TD: 121178 Reg No: (b)(7)(E)

Author (b)(6);(b)(7)(C)

ODEQ

Addressed To:

Location:

ODEQ

Due:

05/11/2012

Received:

5/1/2012

Date Sent:

Security:

A-AES

Response:

Abstract:

Freedom Pharmaceuticals Inc 2012 procurement qutoa request oxycodone

Signature:

C. Sannerud

Doc Categories:

Doc Types:

(b)(6);(b)(7)(C)

OD

To Be Signed

05/08/2012 5/1/2012

Action: Requested Activity:

Response Notes:



Subject Date

Freedom Pharmaceuticals, Inc (b)(4);(b)(7)(E)
2012 Procurement Quota Increase Request

Oxycodone

(DFN: 630-08.2)

1 2012

MAY

To

Barbara Boockholdt

Chicf

Regulatory Section

Office of Diversion Control

From

Christine A. Sannerud, Ph.D.

Chief

Drug & Chemical Evaluation Section

Office of Diversion Control

Background:

As a result of the recent increase in the diversion and abuse of oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2011 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for oxycodone.



Date MAY 0 1 2012
Barbara J. Boockholdt, Chief Regulatory Section Office of Diversion Control
am requesting a review of Freedom on whether the applicant's customers are der to show cause or immediate suspension order.  Customers. The names of the customers were runield investigations. The DEA registration number tions were current. These checks yielded the
ation was found
or deny quota requests from these registrants.
please fell free to contact me $\binom{(b)(6);(b)(7)(}{C)}$ or SC
֡֡֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜

SBF-CM Folder Details

Folder ID: 121262 Reg No: (b)(7)(E)

Author: (b)(6);(b)(7)(C) Addressed To:

 Location:
 ODEQ

 Due:
 05/13/2012

 Received:
 5/3/2012

Date Sent: 5/14/2012

Security: A-AES Response:

**Abstract:** (b)(4) 2012 procurement quota request for hydrocodone

Signature: J. Rannazzisi

Doc Categories: Doc Types:

(b)(6);(b)(7)(C) ODG 05/10/2012 5/11/2012

Action: Recommendation and Comments



Subject (b)(4);(b)(7)(E)

2012 Procurement Quota Increase Request

Hydrocodone (DFN: 630-08.2)

Date

MAY \_ 3 2012

To

Barbara Boockholdt Chief Regulatory Section Office of Diversion Control Christine A Sannerue

Chief

UN Reporting and Quota Section Office of Diversion Control

Background:

As a result of the recent increase in the diversion and abuse of hydrocodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for hydrocodone.



MAY 1 1 2012
, (.\ <i>a</i> , <b>/</b> /./ <b>#</b>
ra J. Boockholdt, Chief
atory Section (ODG)
e of Diversion Control
tomers:
ently Under Review/Investigation
rently Under Review/Investigation

# SBF-CM Folder Details

Folder ID: 121261

Reg No:

(b)(7)(E)

Author (b)(6);(b)(7)(C)

Addressed To:

Location:

ODEQ

Due:

05/13/2012

Received:

5/3/2012

Date Sent:

5/8/2012

Security: Abstract: A-AES

Response:

Aidarex

Aidarex 2012 procurement quota increase request for oxycodone

Signature:

(b)(6);(b)(7)(C)

Doc Categories:

Doc Types:

(b)(6);(b)(7)(C)

ODG

05/10/2012 5/7/2012

Action:

Recommendation and Comments

Requested Activity: Response Notes:

4/27/2015 11:26:33 AM



Subject Date

Aidarex (b)(4);(b)(7)(E)

2012 Procurement Quota Increase Request

Oxycodone

(DFN: 630-08.2)

MAY 3 2012

То

Barbara Boockholdt

Chief

Regulatory Section

Office of Diversion Control

From

Christine A. Sannerud Ph.D

Chief

UN Reporting and Quota Section

Office of Diversion Control

Background:

As a result of the recent increase in the diversion and abuse of oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for hydrocodone.

ODQ notes from the attached documents that this registrant has procured oxycodone finished dosage forms in 2011 and 2012 without a quota.



Subject	Date
$Aidarex^{(b)(4);(b)(7)(E)}$	
2012 Procurement Quota Increase Request	
Oxycodone	MAY 0 7 2010
(DFN:630-08.2)	MAY 0 7 2012
To From	ann ( the 1)
Christine A. Sannerud, Ph.D, Chief  Barbara V. Boockholdt, Chief	
UN Reporting and Quota Section Regulatory Section	
Office of Diversion Control  Office of Diversion Control	
On May 3, 2012, this section received your memorandum requesting a review of Aidarex's customers list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.  Aidarex provided a list of customers. The names of the customers were run through NADDIS to determine if there were any open field investigations. The DEA registration numbers were also run through RICS to determine if the registrations were current. These checks yielded the following results:	
No derogatory information was found	
DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by Freedom Pharmaceuticals for the quota increase.	
If you have any questions pertaining to this information, please fell (b)(6);(b)(7)(C)	free to contact me $\binom{(b)(6);(b)(7)(}{C)}$ or SC

SBF-CM **Folder Details** 

Folder ID: 121263

Reg No:

Author: (b)(6);(b)(7)(C)

ODEQ

Addressed To:

Location:

ODEQ

Due:

05/13/2012

Received:

5/3/2012

Date Sent:

5/8/2012

Security:

A-AES

Response:

2012 procurement quota increase request for oxycodone

Abstract: Signature:

(b)(6);(b)(7)(C)

**Doc Categories:** 

Doc Types:

(b)(6);(b)(7)(C)

ODG

05/10/2012 5/7/2012

Action:

Recommendation and Comments



Subject (b)(4);(b)(7)(E)

2012 Procurement Quota Increase Request

Oxycodone

(DFN: 630-08.2)

Date

MAY 3 2012

To

Barbara Boockholdt Chief Regulatory Section

Office of Diversion Control

Christine A. S

Chief

UN Reporting and Quota Section Office of Diversion Control

#### Background:

As a result of the recent increase in the diversion and abuse of oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for hydrocodone.



Subject  (b)(4);(b)(7)(E)  2012 Procurement Quota Increase Request Oxycodone (DFN: 630-08.2)	MAY 0 7 2012
UN Reporting and Quota Section (ODQ)  Regulat	a J. Boockholdt, Chief tory Section (ODG) of Diversion Control
On May 3, 2012, this section received your memorandum requesting a review of a quota increase submitted by ODQ is requesting a review of customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.  ODGR conducted NADDIS and CSA reviews of approximately twenty-three (23) of (b)(4) customers	
as well as on (b)(4)  The following information was found on one of (b)(4) customer:	
Because one of $(b)(4)$ customers is currently under review/involved adjust the quota allotted to $(b)(4)$ accordingly.  If you have any questions pertaining to this information, please fee $(b)(6)(b)(7)(C)$	

SBF-CM Folder Details

Folder ID: 121412 Reg No: (b)(7)(E)

Author (b)(6);(b)(7)(C) Addressed To:

Location:

Location: ODEQ

Due: 05/20/2012

Received: 5/10/2012 Date Sent: 5/14/2012

Security: A-AES Response:

Abstract: Sun Pharmaceutical Industries 2012 procurment qutoa increase request for

hydrocodone / oxycodone

Signature: Christine Sannerud

Doc Categories: Doc Types:

(b)(6);(b)(7)(C) ODG 05/17/2012 5/14/2012

Action: Recommendation and Comments



Subject

Sun Pharmaceutical Industries, Inc. (b)(4);(b)(7)(E)

2012 Procurement Quota Increase Request

Hydrocodone / Oxycodone

(DFN: 630-08.2)

Date

MAY 1 0 2012

Τo

Barbara Boockholdt

Chief

Regulatory Section

Office of Diversion Control

From/

Chhistine A. Saylnerud, Ph.D.

Chief

Drug & Chemical Evaluation Section

Office of Diversion Control

#### Background:

As a result of the recent increase in the diversion and abuse of hydrocodone and oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for hydrocodone and oxycodone.



Subject

Sun Pharmaceutical Industries, Inc. (b)(4);(b)(7)(E)

2012 Procurement Quota Increase Request

Hydrocodone/Oxycodone
(DFN:630-08.2)

Τo

Christine A. Sannerud, Ph.D, Chief Drug & Chemical Evalution Section Office of Diversion Control Barbara J. Boockholdt, Chief Regulatory Section Office of Diversion Control

On May 10, 2012, this section received your memorandum requesting a review of Sun Pharmaceuticals' customers list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

Sun Pharmaceuticals provided a list of [b)(4) customer. The name of the customer was run through NADDIS to determine if there were any open field investigations. The DEA registration number was also run through RICS to determine if the registration was current. The check yielded the following results:

### No derogatory information was found

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by Sun Pharmaceuticals for the quota increase.

If you have any questions pertaining to this information, please fell free to contact me (C) or SC

#### SBF-CM **Folder Details**

Author: (b)(6);(b)(7)(C) ODEQ

Addressed To:

Location:

ODEQ

Due:

06/03/2012

Received:

5/24/2012

Date Sent:

Security:

A-AES

Response:

Abstract:

Sovereign 2012 procurement quota increase request for hydrocodone

Signature:

J. Rannazzisi

Doc Categories:

Doc Types:

(b)(6);(b)(7)(C)

Recommendation and Comments

05/31/2012 5/29/2012

Action: Requested Activity:

Response Notes:

5/11/2015 2:36:33 PM

1

### 5

#### Memorandum



Subject Date Sovereign (b)(4);(b)(7)(E)2012 Procurement Quota Increase Request Hydrocodone MAY 2 4 2012 (DFN: 630-08.2) To Barbara Boockholdt Christine A. Sanherud, Ph.D. Chief Chief Regulatory Section UN Reporting and Quota Section Office of Diversion Control Office of Diversion Control

#### Background:

1

As a result of the recent increase in the diversion and abuse of hydrocodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for hydrocodone.

SBF-CM

**Folder Details** 

Folder ID: 121635

Reg No:

(b)(7)(E)

Author (b)(6);(b)(7)(C)

Addressed To:

Location:

ODEQ

Due:

06/03/2012

Received:

5/24/2012

Date Sent:

Security:

A-AES

Response:

Abstract:

Metrics Inc 2012 procurement quota increase request for oxycodone

Signature:

Charistine Sannerud

Doc Categories:

Doc Types:

(b)(6);(b)(7)(C)

ODG

05/31/2012 5/29/2012

Action:

Recommendation and Comments

Requested Activity: Response Notes:



Subject

Metrics, Inc. (b)(4);(b)(7)(E)

2012 Procurement Quota Increase Request

Oxycodone

(DFN: 630-08.2)

Date

MAY 2 4 2012

To

Barbara Boockholdt

Chief

Regulatory Section

Office of Diversion Control

From

Christine A. Sannerud, Ph.D.

Chief

Drug & Chemical Evaluation Section

Office of Diversion Control

#### Background:

As a result of the recent increase in the diversion and abuse of oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2011 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for oxycodone.

Please feel free to contact me if I can provide further assistance in this matter.



Subject (b)(4):(b)(7)(E)	Date	
Metrics, Inc. (b)(4);(b)(7)(E) 2012 Procurement Quota Request	0017	
Oxycodone	MAY 2 5 2012	
(DFN:630-08.2)		
То	From Soule holdt	
Christine A. Sannerud, Ph.D, Chief	Barbara J. Boockholdt, Chief	
Drug & Chemical Evaluation Section	Regulatory Section Office of Diversion Control	
Office of Diversion Control  Office of Diversion Control		
On May 24, 2012, this section received your memorandum requesting a review of Metrics, Inc.'s customers list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.  Metrics, Inc. provided a list of (b)(4) customer. The name of the customer was run through NADDIS to determine if there were any open field investigations. The DEA registration number was also run through RICS to determine if the registration was current. This check yielded the following result:		
No derogatory information was found		
DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by Metrics, Inc. for the quota increase.		
If you have any questions pertaining to this information, please fell free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)		



Subject (b)(4);(b)(7)(E)	Date
2012 Procurement Quota Increase Request	0 T. AAM
Hydrocodone	JUN 0 7 2012
(DFN:630-08.2)	
То	From Co. al. L. C.
Christine A. Sannerud, Ph.D, Chief	Barbara J. Boockholdt, Chief
Drug & Chemical Evalution Section	Regulatory Section
Office of Diversion Control	Office of Diversion Control
to determine if there were any open field investigation	it's customers are currently under investigation or are ispension order.  e names of the customers were run through NADDIS and The DEA registration numbers were also run
through RICS to determine if the registrations were c	urrent. These checks yielded the following results:
(b)(4);(b)(7)(E)	Retired 6/1/12
DEA does not have sufficient grounds to limit, restrict Based on this information, ODG suggests that you proby (b)(4) for the quota increase.	et, or deny quota requests from these registrants.  oceed with the completion of the request submitted
If you have any questions pertaining to this information (b)(6);(b)(7)(C)	on, please feel free to contact me (b)(6);(b)(7)() or SC



Subject  (b)(4)  2012 Procurement Quota Increase Request Oxycodone (DFN: 630-08.2)  To  From Saulan Boochh Lat			
2012 Procurement Quota Increase Request Oxycodone (DFN: 630-08.2)  To  From Darban Booch heldt			
Oxycodone (DFN: 630-08.2)  To  From Saulan Booch heldt			
To From Docal he lat			
To From Boach he lat			
Darbara Booch he let			
Darbara Booch he let			
Darbara Booch he let			
Christine A. Sannerud, Ph.D., Chief  Barbara J. Bookholdt, Chief  Regulatory Section (ODG)			
Office of Diversion Control  Office of Diversion Control			
On June 7, 2012, this section received your memorandum requesting a review of a quota increase submitted by (b)(4) ODQ is requesting a review of (b)(4) sustomer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.			
ODGR conducted NADDIS and CSA reviews of approximately ninety-five (95) of (b)(4) customers as			
well as an in-depth investigation of (b)(4)			
The below listed information was found on (b)(4) customers:			
Currently Under Review/Investigation			
Currently Under Review/Investigation			
(b)(4);(b)(7)(E)			
Currently Under Review/Investigation (b)(4);(b)(7)(E)			
Currently Under Review/Investigation			
(b)(4);(b)(5);(b)(7)(E)			
Currently Under Review/Investigation			
(b)(4);(b)( 7)(E)			

Currently Under Review/Investigation (b)(4);(b)(7)(E)
(b)(4);(b)(7)(E)  Currently Under Review/Investigation
Currently Under Review/Investigation (b)(4);(b)(7)(E)
Currently Under Review/Investigation (b)(4);(b)(7)(E)
Currently Under Review/Investigation (b)(4);(b)(7)(E)
(b)(4);(b)(7)(E) Retired
Based upon a review of (b)(4) customers, ODG recommends that ODQ adjust the quota granted to company. Nine (9) of (b)(4) customers are under Review/Investigation and one (I) is retired.
Quota to (b)(4) should be reduced by at least the total kilogram amounts sold by the company to the above listed customers.
If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7) or SC (c)



Subject	Date
Sovereign (b)(4);(b)(7)(E)	Dute
2012 Procurement Quota Increase Request	
Hydrocodone	·
(DFN:630-08.2)	JUN 2 7 2012

To

Christine A. Sannerud, Ph.D, Chief Drug & Chemical Evaluation Section Office of Diversion Control Barbara J. Bookholdt, Chief Regulatory Section Office of Diversion Control

On June 27, 2012, this section received your memorandum requesting a review of Sovereign's customers list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

Sovereign provided a list of [b)(4) customer. The name of the customer was run through NADDIS to determine if there were any open field investigations. The DEA registration number was also run through RICS to determine if the registration was current. This check yielded the following result:

#### No derogatory information was found

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by Sovereign for the quota increase.

If you have any questions pertaining to this information, please fell free to contact me (b)(6);(b)(7)(C) or SC



Roadrunner Pharmacy (b)(4);(b)(7)(E)
2012 Procurement Quota
Hydrocodone
(DFN: 630-08.2)

Date

JUL 19 2012

Τo

Christine A. Sannerud, Ph.D., Chief UN Reporting & Quota Section (ODQ) Office of Diversion Control Barbara J. Boockholdt, Chief Regulatory Section (ODG) Office of Diversion Control

On July 17, 2012, this section received your memorandum requesting a review of a quota increase submitted by Roadrunner Pharmacy. ODQ is requesting a review of Roadrunner Pharmacy's customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately (b)(4) of Roadrunner's customers as well as an in-depth investigation of Roadrunner Pharmacy.

The below listed information was found on Roadrunner's customers:

#### NO DEROGATORY INFORMATION WAS FOUND

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by Roadrunner Pharmacy for the quota increase.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC



Subject (b)(4);(b)(7)(E)	Date
2012 Procurement Quota Increase Request Oxycodone (DFN:630-08.2)	AUG 0 1 2012
UN Reporting & Quota Section Res	bara J. Boockholdt, Chief gulatory Section ice of Diversion Control
On July 17, 2012, this section received your memorandum req list, specifically, information on whether the applicant's custor the subject of an order to show cause or immediate suspension  (b)(4) provided a list of five (05) customers. The names to determine if there were any open field investigations. The I through RICS to determine if the registrations were current.	mers are currently under investigation or are order.  of the customers were run through NADDISDEA registration numbers were also run
(b)(4);(b)(7)(E)	Currently Under/Review Investigation Currently Under/Review Investigation
DEA does not have sufficient grounds to limit, restrict, or deny  If you have any questions pertaining to this information, please (b)(6),(b)(7)(C)	



Subject (b)(4);(b)(7)(E)  2012 Procurement Quota Increase Request Oxycodone (DFN: 630-08.2)	AUG 2 2 2012		
Drug & Chemical Evaluation Section Regu	ara J. Boockholdt, Chief elatory Section (ODG) e of Diversion Control		
On August 2, 2012, this section received your memorandum requesting a review of a quota increase submitted by (b)(4) DDQ is requesting a review of (b)(4) customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.  ODGR conducted NADDIS and CSA reviews of approximately sixty one (61) of (b)(4) customers as well as an in-depth investigation of (b)(4)			
	ently Under Review/Investigation		
(b)(4);(b)(7)(E)	ntly Under Review/Investigation		
(b)(4);(b)(7)(E)	ntly Under Review/Investigation  ntly Under Review/Investigation		

(b)(4);(b)(7)(E)	Currently Under Review/Investigation
(b)(4);(b)	Currently Under Review/Investigation
(b)(4	Currently Under Review/Investigation
based upon a review of (b)(4) customers, ranted to this company by at least the total kilogram	ODG recommends that ODQ adjust the quota amounts sold to the above listed customers.
f you have any questions pertaining to this information	on, please feel free to contact me (b)(6);(b)(7) or PA



Subject (b)(4);(b)(7)(E)  2012 Procurement Quota Increase Request Hydrocodone (DFN: 630-08.2)	SEP 1 0 2012		
UN Reporting and Quota Section (ODQ) Regu	ara J. Boockholdt, Chief  clatory Section (ODG)  se of Diversion Control		
On August 29, 2012, this section received your memorandum requesting a review of a quota increase submitted by (b)(4) ODQ is requesting a review of (b)(4) customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.  ODGR conducted NADDIS and CSA reviews of approximately ninety-seven (97) of (b)(4) customers as well as an in-depth investigation of (b)(4)			
The below listed information was found on (b)(4) customers  Order	r to Show Cause Requested to CC		
	ently Under Review/Investigation		
(b)(4);(b)(7)(E)	ently Under Review/Investigation		
	ently Under Review/Investigation  [(b)(4);(b)(7)( E)  ently Under Review/Investigation [(b)(4);(b)(7)(		

	Currently Under Review/Investigation	( E
	Currently Under Review/Investigation  (b)(4);(b)(7)(E)	[
	Currently Under Review/Investigation (b)(4);(b)(7)(E)	7
	Currently Under Review/Investigation (b)(4);(b)(7)(E)	_
	(b)(4);(b)(7)(E) Currently Under Review/Investigation	
		his
sed upon a review of (b)(4) mpany. Ten (10) of (b)(4)	customers, ODG recommends that ODQ adjust the quota granted to t customers are under Review/Investigation.	1113



Mikart Inc. (DEA (b)(4);(b)(7)(E)

2012 Procurement Quota Increase Request
Hydrocodone
(DFN:630-08.2)

SEP 1 2 2012

Τo

Christine A. Sannerud, Ph.D, Chief UN Reporting and Quota Section Office of Diversion Control Barbara J. Bookholdt, Chief

Regulatory Section

Office of Diversion Control

On September 11, 2012, this section received your memorandum requesting a review of Mikart Inc.'s customers list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

Mikart Inc. provided a list of (b)(4) customers. The names of the customers were run through NADDIS to determine if there were any open field investigations. The DEA registration numbers were also run through RICS to determine if the registrations were current. These checks yielded the following results:

#### No derogatory information was found

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by Freedom Pharmaceuticals for the quota increase.

If you have any questions pertaining to this information, please fell free to contact me  $\frac{(b)(6);(b)(}{7)(C)}$  or SC  $\frac{(b)(6);(b)(7)(C)}{(b)(6);(b)(7)(C)}$ 



Subject (b)(4),(b)(7)(E)	Date
2012 Procurement Quota Increase Request Hydrocodone (DFN:630-08.2)	SEP 1 7 2012
To Christine A. Sannerud, Ph.D, Chief	Barbara J. Boockholdt, Chief
UN Reporting and Quota Section Office of Diversion Control	Regulatory Section Office of Diversion Control
On September 10, 2012, this section received your mem submitted by (b)(4) ODQ is requesting a review of (to on whether the applicant's customers are currently under show cause or immediate suspension order.	customers list, specifically, information
ODGR conducted NADDIS and CSA reviews of approx customers as well as on (b)(4)	timately one hundred fifty-nine (159) of (b)(4)
The below listed information was found on $(b)(4)$	ustomers:
(b)(4);(b)(7)(E)	Retired in 7/2012
	Retired 7/05/2012
(b)(4);(b)(7)(E)	Currently Under Review/Investigation
	Currently Under Review/Investigation
The product of the condition of the cond	ommends that ODQ adjust the quota granted to ly retired and three (3) customers are under
If you have any questions pertaining to this information, (b)(6);(b)(7)(C)	, please feel free to contact me (b)(6);(b)(7)( or SC




Subject  (b)(4);(b)(7)(E)  2012 Procurement Quota Increase Request Oxycodone (DFN: 630-08.2)	SEP 1 7 2012		
Christine A. Sannerud, Ph.D., Chief Barbara Drug & Chemical Evalutaion Section (ODQ) Regular	Booch holdt a J. Boockholdt, Chief tory Section (ODG) of Diversion Control		
On August 31, 2012, this section received your memorandum requesting a review of a quota increase submitted by (b)(4) ODQ is requesting a review of (b)(4) customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.			
ODGR conducted NADDIS and CSA reviews of approximately ninety-six (96) of (b)(4) customers as well as an in-depth investigation of (b)(4) customers:			
Currently Under Review/Investigation			
Currently Under Review/Investigation  (b)(4);(b)(7)(E)			
(b)(4);(b)(7)(E) Currently Under Review/Investigation			
Currently Under Review/Investigation (b)(4);(b)(5);(b)(7)(E)			
(b)(4);(b)(7)(E)	tly Under Review/Investigation		

	(b)(4);(b)(7)(l	Currently Under Review/Investigation
	(b)(4);(b)(7)(E)	Currently Under Review/Investigation
	(b)(4);(b)(	Currently Under Review/Investigation
	(b)(4);(b)(1	Currently Under Review/Investigation (7)(E)
	(b)(4)	Currently Under Review/Investigation
(b)(4);(	;(b)(7)(E)	Retired
	<u> </u>	ecommends that ODQ adjust the quota granted to thi Review/Investigation and one (1) is retired.
Quota to above li	should be reduced by at least the tot isted customers.	al kilogram amounts sold by the company to the
If you h: (b)(6);(b)(7)	nave any questions pertaining to this information	on, please feel free to contact me (b)(6);(b)(7) or PA



Subject	Date
(b)(4);(b)(7)(E)  2012 Procurement Quota Increase Request Oxycodone (DYN) (200, 200, 2)	OCT 3 1 2012
(DFN: 630-08.2)	
To Christine A. Sannerud, Ph.D., Chief UN Reporting and Quota Section	From  Barbara J. Boockholdt,  Chief  Regulatory Section
Office of Diversion Control	Office of Diversion Control
On September 18, 2012, this section received your me submitted by (b)(4) ODQ is requesting a specifically, information on whether the applicant's cusubject of an order to show cause or immediate suspen ODGR conducted NADDIS and CSA reviews of approximation of the customers as well as an in-depth investigation.	review of (b)(4) customer list, customers are currently under investigation or are unsion order. (b)(4) 7)(E)
The below listed information was found on (b)(4)	customers:
(b)(4);(b)(	<u> </u>
	Currently Under Review/Investigation (b)(E) (7)(E)
(b)(4);(b)(7)(E)	Currently Under Suspension
(b)(4);(b	Currently Under Under/Review
	Currently Under Under/Review
(b)(4);(	(b)(7)(E)



3	(b)(4);(b)(7)( E)
	ler-Review/Investigation ler Suspension
(b)(4);(b)(7)(E) Currently Un	der Review/Investigation (b)(4);(b)(7)(E)
Based upon a review of customers, ODG recommend granted to this company.	ds that ODQ adjust the quota
<del></del>	s are under Currently Under
Review/Investigation, Two (2) are Currently Under Suspension, and one (b)(4);(b)(7)	
Quota to (b)(4) should be reduced by at least the total kilograto to the above listed customers.	rm amounts sold by the company
If you have any questions pertaining to this information, please feel free t	o contact me $\binom{(b)(6);(b)(7)(}{C)}$ or PA



Subject	Date
(b)(4);(b)(7)(E)	Date
2012 Procurement Quota Increase Request	
Oxycodone	NOV o a con-
(DFN: 630-08.2)	NOV 0 1 2012
To Fr	rgm / C a / /
Christine A. Sannerud, Ph.D.,	Barbara J. Boockholdt,
Chief Chief	Chief
	Regulatory Section
	Office of Diversion Control
On September 27, 2012, this section received your memorar submitted by (b)(4) ODQ is requesting a review of (information on whether the applicant's customers are current order to show cause or immediate suspension order.	b)(4) customer list, specifically,
ODGR conducted NADDIS and CSA reviews of approxima (b)(4) customers as well as an in-depth investigation of (b)(4)	ately one hundred and nine (109) of (b)(4)
The below listed information was found on [b)(4) cu	stomers:
	urrently Under Review/Investigation
(b)(4);(b)(7)(E)	
Oı	rder to Show Cause Requested————E)
	urrently Under Review/Investigation (b)(4);(b)(7)(
	urrently Under Review/Investigation
(b)(4);(b)(5);(b)(7)(E)	
	urrently Under Review/Investigation
(b)(4);(b)(7)(E)	TITULIA OTTO I ITOLIAMIANI POSIBATION

	Currently Under Review/Investigation
(b)(4);(b)(7)(	E)
	Currently Under Review/Investigation
(b)(4);(b)(	(7)(E)
(b)(4);(b)(7)(E)	Currently Under Review/Investigation
	Currently Under Review/Investigation
(b)(4);(b)	(7)(E)
(b)(4);(b)(7)(E)	Retired 6/5/2012
(b)(4);(b)(7)(E)	Currently Under Review/Investigation
	Currently Under Suspension
(b)(4	);(b)(7)(E)
this company. Nine (9) of $(b)(4)$ customers a issued an Order to Show Cause (OTSC), one (1) is	OG recommends that ODQ adjust the quota granted to are under Review/Investigation, one (1) has been Under Suspension and one (1) is Retired (b)(4);(b)(7)(E)
Quota to b)(4) should be reduced by at least the above listed customers.	the total kilogram amounts sold by the company to
If you have any questions pertaining to this information (b)(6);(b)(7)(C)	tion, please feel free to contact me (b)(6);(b)(7)( or PA




Subject (b)(4);(b)(7)(E)				Date	
	ment Quota Increase	Paguast			
Hydrocodone	•	Request		New O. C. and a	
(DFN: 630-0				NOV 0 9 2012	
(======================================	,				
То			From		
Christine A. S	Sannerud, Ph.D.,		Barbara	Bookholdt, 119.12	
Chief	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		Chief		
UN Reporting	and Quota Section		Regulato	ory Section	
	ersion Control		Office o	f Diversion Control	
On October 1	3, 2012, this section 1	received your men	norandum requ	esting a review of a quota incre	ase
submitted by	'八+'/ [OI	DQ is requesting a			
- 1					
specifically, in	formation on whether			currently under investigation or	are
specifically, in				currently under investigation or	are
specifically, in subject of an o	formation on whether order to show cause o	or immediate suspe	ension order.		
specifically, in subject of an o	nformation on whether order to show cause of cted NADDIS and Co	or immediate suspo SA reviews of app	ension order. proximately on	currently under investigation or a currently under	
specifically, in subject of an o	offormation on whether order to show cause of cted NADDIS and Co mers as well as an in	SA reviews of approached the subset of subset	ension order. proximately on		
specifically, in subject of an o	nformation on whether order to show cause of cted NADDIS and Co	SA reviews of approached the subset of subset	ension order. proximately on on of (b)(4)		
specifically, in subject of an o	offormation on whether order to show cause of cted NADDIS and Co mers as well as an in	SA reviews of approached the subset of subset	ension order.  proximately on on of (b)(4)  pusto	e hundred forty-four (144) of (b) mers:	0(4)
specifically, in subject of an o	offormation on whether order to show cause of cted NADDIS and Co mers as well as an in	or immediate suspensed and sus	ension order.  proximately on on of (b)(4)  pusto	e hundred forty-four (144) of (b)	0(4)
specifically, in subject of an o	offormation on whether order to show cause of cted NADDIS and Co mers as well as an in	SA reviews of approached the subset of subset	ension order.  proximately on on of (b)(4)  pusto	e hundred forty-four (144) of (b) mers:	0(4)
specifically, in subject of an o	order to show cause of the order to show cause o	or immediate suspensed and sus	ension order.  proximately on on of (b)(4)  pusto  Currentle (7)(E)	e hundred forty-four (144) of (b) mers: y Under Review/Investigation	
specifically, in subject of an o	offormation on whether order to show cause of cted NADDIS and Co mers as well as an in	or immediate suspensed and sus	ension order.  proximately on on of (b)(4)  pusto  Currentle (7)(E)	e hundred forty-four (144) of (b) mers:	
specifically, in subject of an o	order to show cause of the order to show cause o	or immediate suspensed and sus	currentl	mers:  y Under Review/Investigation  y Under Review/Investigation	
specifically, in subject of an o	order to show cause of the order to show cause o	or immediate suspensed and sus	currentl	e hundred forty-four (144) of (b) mers: y Under Review/Investigation	(b)
specifically, in subject of an o	order to show cause of the order to show cause o	or immediate suspensed and sus	currentl	mers:  y Under Review/Investigation  y Under Review/Investigation	(b)
specifically, in subject of an o	order to show cause of the order to show cause o	or immediate suspensed and sus	currentl	w Under Review/Investigation  y Under Review/Investigation	(b) (7) (c)
specifically, in subject of an oronge conduction (b)(4) custout The below lis	order to show cause of the order to show cause o	or immediate suspensed and sus	currentl	mers:  y Under Review/Investigation  y Under Review/Investigation	(b) (7) (b) (7) (c)
specifically, in subject of an o	order to show cause of the order to show cause o	or immediate suspensed and sus	currentl	w Under Review/Investigation  y Under Review/Investigation	(b) (7) (c)

(b)(4);(b)(5	Currently Under Review/Investigation 5);(b)(7)(E)
(b)(4);(b)(7)	Currently Under Review/Investigation
(b)(4);(b)(7	Currently Under Review/Investigation (7)(E)
(b)(4);(b)(7)(E)	Currently Under Review/Investigation
Based upon a review of (b)(4) customers, C granted to this company. Nine (9) of (b)(4) (b)(4);(b)(5);(b)(7)(E)	DDG recommends that ODQ adjust the quota customers are under Review/Investigation,
Quota to (b)(4) should be reduced by at least to the above listed customers.	st the total kilogram amounts sold by the company
If you have any questions pertaining to this information (b)(6);(b)(7)(C)	n, please feel free to contact me (b)(6);(b)(7) or PA
Ce: ChristineASannerud, Ph.D /Chief/ODQ/UN Report	rting and Quota Section
Cc: ODG (b)(6);(b)(7)(C)	10/10/2012
Cc: ODGR   11/9/2012: RegD	JOC:10/18/2012



Subject (b)(4);(b)(7)(E)	Date
2012 Procurement Quota Increase Request	
Oxycodone	No.
(DFN: 630-08.2)	NOV 2 9 2012
То	From
	Barbara J. Bookholdt,
Christine A. Sannerud, Ph.D.,	J
Chief	Chief
UN Reporting and Quota Section	Regulatory Section
Office of Diversion Control	Office of Diversion Control
On November 13, 2012, this section received your mer submitted by (b)(4) ODQ is requesting a review of (b) whether the applicant's customers are currently under it cause or immediate suspension order.  ODGR conducted NADDIS and CSA reviews of approwell as an in-depth investigation of (b)(4)  The below listed information was found on (b)(4)	customer list, specifically, information on nvestigation or are subject of an order to show
(b)(4);(b)(5);(	(b)(7)(E)
	Currently Under Review/Investigation
(b)(4);(b	
(-/(-//(-	
	Currently Under Suspension
(b)(4);(b	)(7)(E)





Subject (b)(4);(b)(7)(E)	Date
2012 Procurement Quota Increase Request	
Hydrocodone	NOV 2 9 2012
(DFN:630-08.2)	THUY LO LUIE
То	From . ( )
Christine A. Sannerud, Ph.D, Chief	Barbara J. Boogkholdt, Chief
Drug & Chemical Evaluation Section	Regulatory Section/ODG
Office of Diversion Control	Office of Diversion Control
(b)(4)  name of the customer was run through NADDIS to d ODGR has checked with the DEA/(b)(7)(E) numbers were also run through RICS to determine if the following results:	provided a list of one (1) customer. The
(D)(+),(U)(1)(L)	
At this time it does not appear that DEA has sufficient requests from this registrant. Based on this informat completion of the request submitted by (b)(4) their quota.	
If you have any questions pertaining to this information (b)(6);(b)(7)(C)	ion, please fell free to contact me (b)(6);(b)(7)( or PA